Furthermore, inhibiting Akt reverses acquired sorafenib-resistance by converting autophagy from a cytoprotective role to a death-promoting one in sorafenib-resistant hepatocellular carcinoma cells [13]. Here, AKT1 is linked to hepatocellular carcinoma.